Previous close | 0.0039 |
Open | 0.0045 |
Bid | 0.0000 x 0 |
Ask | 0.0000 x 0 |
Day's range | 0.0028 - 0.0045 |
52-week range | 0.0001 - 0.2625 |
Volume | |
Avg. volume | 2,610,252 |
Market cap | 156,434 |
Beta (5Y monthly) | 1.66 |
PE ratio (TTM) | 0.01 |
EPS (TTM) | 0.2400 |
Earnings date | N/A |
Forward dividend & yield | N/A (N/A) |
Ex-dividend date | N/A |
1y target est | N/A |
MELBOURNE, Australia, February 22, 2024--The compassionate use study results highlight clinical effects studied in 46 patients with advanced metastatic cancers of different origin
MELBOURNE, Australia, January 16, 2024--The advancement of our growing IP portfolio in these major regions gives us confidence that we are leading a novel approach using proenzyme technology
MELBOURNE, Australia, December 18, 2023--We are offering an attractive investment opportunity to become involved in the development of a novel, first-in-class cancer therapy